Brief: Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 Raise Trial In Refractory Status Epilepticus At The Neurocritical Care Society 2024 Annual Meeting
17/10/2024 12:39
Oct 17 (Reuters) - Marinus Pharmaceuticals Inc MRNS.O :
* MARINUS PHARMACEUTICALS PRESENTS CLINICAL DATA FROM
PIVOTAL
PHASE 3 RAISE TRIAL IN REFRACTORY STATUS EPILEPTICUS AT THE
NEUROCRITICAL CARE SOCIETY 2024 ANNUAL MEETING
Source text for Eikon: ID:nBw2ZB8m2a
Further company coverage: MRNS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marinus Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Axsome Therapeutics, Ducommun, Vacasa
Brief: Immedica To Acquire Biopharmaceutical Company Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Appfolio, S&P Global, Uber
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group